Previous Section | Index | Home Page |
Mr. Nicholas Winterton: To ask the Secretary of State for Trade and Industry what steps he is taking to ensure that the interests of the Caribbean banana growers are recognised in the European Union negotiations on new trading arrangements. [79097]
Mr. Rooker:
I have been asked to reply.
13 Apr 1999 : Column: 97
The Government will continue to take the interests of Caribbean banana growers fully into account, along with our other international commitments, in any negotiations to change the EU banana regime.
Yvette Cooper: To ask the Secretary of State for Health if he will list the pilot projects instigated by his Department since 1 May 1997, indicating the area in which each pilot took, or is taking, place. [72637]
Mr. Denham: Pilot projects instigated by the Department since 1 March 1997 are:
13 Apr 1999 : Column: 98
13 Apr 1999 : Column: 99
13 Apr 1999 : Column: 100
Dr. Cable:
To ask the Secretary of State for Health if he will list the (a) average, (b) maximum and (c) minimum waiting times for thallium scans (1) for each
13 Apr 1999 : Column: 101
year over the last five years at each of the nuclear medicine centres that provide this facility in the United Kingdom; [73476]
Mr. Denham:
Information on waiting times for this procedure is not available.
Mr. Maclean:
To ask the Secretary of State for Health what warnings are given to patients of the dangers of myelography. [73950]
Mr. Hutton:
Patients are entitled to receive sufficient information in a way they can understand about the proposed treatments/procedures (which would include myelography), the possible alternatives, and any substantial risks, so that they can make an informed decision. Clinicians should use their skill, knowledge and experience to weigh carefully the likely benefits of any treatment or procedure against the anticipated risk and, following discussion with the patient, to exercise their clinical judgment and expertise accordingly.
Mr. Cousins:
To ask the Secretary of State for Health what is the current unit cost in the NHS of each accepted treatment for erectile dysfunction disorder by (a) prescribable drug and (b) other means. [76133]
Mr. Denham:
The information requested is not available in any comparable form.
Mr. Cousins:
To ask the Secretary of State for Health what was the total cost per adult male of GP-prescribed drug treatments for erectile dysfunction disorders in (a) England, (b) each English region and (c) each English health authority area in the most recent complete year available. [76132]
Mr. Denham:
The information requested is shown in the table.
(2) in (i) the United Kingdom and (ii) the Greater London area for those aged (A) 0-25 years, (B) 25-50 years and (C) over 50 years. [73475]
Notes:
1. The information is from the Prescribing Analyses and Cost system (PACT) which is based on all prescriptions prescribed by General Practitioners which are dispensed.
2. The population figures used are based on the Office for National Statistics mid year resident population projections for 1998, 1996 based.
3. The net ingredient cost is the basic cost of a drug which does not take account of discounts, dispensing costs, fees or prescription charges income.
4. Drugs used for the treatment of erectile dysfunction are defined as those in the British National Formulary paragraph 7.4.5, "Drugs for impotence".
13 Apr 1999 : Column: 103
Next Section | Index | Home Page |